PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors

被引:1
|
作者
Fang, Yong [1 ]
Zhang, Xuhui [2 ]
Guo, Yuyang [1 ]
Dong, Yi [1 ]
Liu, Wenfei [1 ]
Hu, Xihua [1 ]
Li, Xuxin [1 ]
Gao, Daifeng [3 ]
机构
[1] 305 Hosp Peoples Liberat Army, Dept Gen Surg, Beijing 100017, Peoples R China
[2] 305 Hosp Peoples Liberat Army, Dept Anesthesiol, Beijing 100017, Peoples R China
[3] Guard Bur Joint Staff Cent Mil Commiss, Dept Hlth, Beijing 100013, Peoples R China
关键词
Colorectal tumor; PKMYT1; CCNE1; CDK1; & gamma; H2AX; DNA-DAMAGE; COLON-CANCER; CYCLIN; REPAIR; CELLS; SENSITIVITY; INHIBITION; GAMMA-H2AX; TISSUE; BCL-2;
D O I
10.1007/s12013-023-01158-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer is a malignant tumor with higher morbidity and mortality. The purpose of this study is to investigate whether inhibition of Protein Kinase, Membrane Associated Tyrosine/Threonine 1 (PKMYT1) affects tumor cell proliferation, survival and migration in colon tumors with high Cyclin E1 (CCNE1) expression. PcDNA3.1-CCNE1 vector and si-PKMYT1 were transfected in SW480 cells by Lipofectamine 2000. Q-PCR and western blot assay were processed to detect the expression. Transwell assay and Edu assay were undertaken to verify the migration and proliferation. CCNE1 promotes the proliferation and migration of SW480. Silencing of PKMYT1 inhibited the proliferation of tumor cells. Silencing the expression of PKMYT1 under the premise of overexpression of CCNE1, the level of Cyclin Dependent Kinase 1 (CDK1)-PT14 was reduced, indicating that the cell cycle was blocked. The expression of ?H2AX increased significantly, indicating that the DDR pathway of tumor cells was activated and DNA damage accumulated. The results of immunofluorescence microscopy showed significantly increased expression of DNA damage-associated marker (?H2AX: H2AX Variant Histone). In CCNE1 amplificated colorectal tumor cells, knockdown of PKMYT1 reduced cells in S phase, inhibited cell proliferation and promoted cell apoptosis, confirming that PKMYT1 was a potential therapeutic target for colorectal tumor. This study may verify a potential therapeutic target and provide a new idea for the treatment of colorectal cancer in the future.
引用
收藏
页码:569 / 576
页数:8
相关论文
共 50 条
  • [1] PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors
    Yong Fang
    Xuhui Zhang
    Yuyang Guo
    Yi Dong
    Wenfei Liu
    Xihua Hu
    Xuxin Li
    Daifeng Gao
    [J]. Cell Biochemistry and Biophysics, 2023, 81 : 569 - 576
  • [2] CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
    David Gallo
    Jordan T. F. Young
    Jimmy Fourtounis
    Giovanni Martino
    Alejandro Álvarez-Quilón
    Cynthia Bernier
    Nicole M. Duffy
    Robert Papp
    Anne Roulston
    Rino Stocco
    Janek Szychowski
    Artur Veloso
    Hunain Alam
    Prasamit S. Baruah
    Alexanne Bonneau Fortin
    Julian Bowlan
    Natasha Chaudhary
    Jessica Desjardins
    Evelyne Dietrich
    Sara Fournier
    Chloe Fugère-Desjardins
    Theo Goullet de Rugy
    Marie-Eve Leclaire
    Bingcan Liu
    Vivek Bhaskaran
    Yael Mamane
    Henrique Melo
    Olivier Nicolas
    Akul Singhania
    Rachel K. Szilard
    Ján Tkáč
    Shou Yun Yin
    Stephen J. Morris
    Michael Zinda
    C. Gary Marshall
    Daniel Durocher
    [J]. Nature, 2022, 604 : 749 - 756
  • [3] CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
    Gallo, David
    Young, Jordan T. F.
    Fourtounis, Jimmy
    Martino, Giovanni
    Alvarez-Quilon, Alejandro
    Bernier, Cynthia
    Duffy, Nicole M.
    Papp, Robert
    Roulston, Anne
    Stocco, Rino
    Szychowski, Janek
    Veloso, Artur
    Alam, Hunain
    Baruah, Prasamit S.
    Fortin, Alexanne Bonneau
    Bowlan, Julian
    Chaudhary, Natasha
    Desjardins, Jessica
    Dietrich, Evelyne
    Fournier, Sara
    Fugere-Desjardins, Chloe
    de Rugy, Theo Goullet
    Leclaire, Marie-Eve
    Liu, Bingcan
    Bhaskaran, Vivek
    Mamane, Yael
    Melo, Henrique
    Nicolas, Olivier
    Singhania, Akul
    Szilard, Rachel K.
    Tkac, Jan
    Yin, Shou Yun
    Morris, Stephen J.
    Zinda, Michael
    Marshall, C. Gary
    Durocher, Daniel
    [J]. NATURE, 2022, 604 (7907) : 749 - +
  • [4] The PKMYT1 inhibitor RP-6306 has synergistic efficacy with carboplatin in CCNE1 amplified tumor models
    Fourtounis, J.
    Gallo, D.
    Roulston, A.
    Stocco, R.
    Martino, G.
    Fournier, S.
    Aguado, E.
    Kryczka, R.
    Bhaskaran, V.
    Morris, S.
    Marshall, C. G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 174 : S61 - S61
  • [5] PKMYT1 as a Potential Target to Improve the Radiosensitivity of Lung Adenocarcinoma
    Long, Huan-ping
    Liu, Jia-qing
    Yu, Yang-yang
    Qiao, Qiao
    Li, Guang
    [J]. FRONTIERS IN GENETICS, 2020, 11
  • [6] CCNE1 Amplification as a Therapeutic Target
    Au-Yeung, George
    Mileshkin, Linda
    Bowtell, David D. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (09) : 1770 - +
  • [7] RP-6306, a novel PKMYT1 inhibitor, demonstrates synthetic lethality as monotherapy and in combination with gemcitabine in CCNE1 amplified cancer cells.
    Fourtounis, Jimmy
    Martino, John
    Stocco, Rino
    Baruah, Prasamit
    Duffy, Nicole
    Gallo, David
    Fournier, Sarah
    Li, JingJing
    Li, Li
    Aguado, Elia
    Petrone, Adam
    Roulston, Anne
    Mamane, Yael
    Morris, Stephen
    Szychowski, Janek
    Papp, Robert
    Zinda, Mike
    Marshall, C. Gary
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [8] Targeting cell cycle dependencies in CCNE1 amplified tumors
    Doberstein, Kai
    Karst, Alison
    Jones, Paul
    Ligon, Azra
    Hirsch, Michelle
    Etemadmoghadam, Dariush
    Hahn, William
    Bowtell, David
    Drapkin, Ronny
    [J]. CANCER RESEARCH, 2017, 77
  • [9] Gene Amplification CCNE1 Is Related to Poor Survival and Potential Therapeutic Target in Ovarian Cancer
    Nakayama, Naomi
    Nakayama, Kentaro
    Shamima, Yeasmin
    Ishikawa, Masako
    Katagiri, Atsuko
    Iida, Kouji
    Miyazaki, Khoji
    [J]. CANCER, 2010, 116 (11) : 2621 - 2634
  • [10] PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target
    Wang, Jianan
    Wang, Lin
    Chen, Saipeng
    Peng, Huahong
    Xiao, Longfei
    Du, E.
    Liu, Yan
    Lin, Dong
    Wang, Yuzhuo
    Xu, Yong
    Yang, Kuo
    [J]. GENE, 2020, 744